Table 3.

Adjusted Incremental Costs, by Adverse Event Category

Adverse event category	Adjusted mean costa		Incremental cost		95% CI for adjusted incremental cost, $
	Patients with adverse events, $	Patients without adverse events, $	Observed, $	Adjusted, $
Respiratory	31,927	7777	23,096	24,150	17,630–30,671
CNS/psychiatric	28,372	6440	20,977	21,932	16,011–27,854
Metabolic/nutritional	27,136	7360	16,022	19,776	14,239–25,314
Skin/subcutaneous tissue	27,147	7964	15,352	19,183	14,195–24,170
General disorder/administration-site condition	25,011	6035	21,084	18,976	13,663–24,289
Pain	26,666	8259	15,951	18,406	13,805–23,008
Cardiovascular	24,119	7726	14,592	16,393	12,131–20,655
Hematologic/lymphatic	23,531	7681	13,851	15,850	11,888–19,813
Gastrointestinal	19,794	6095	13,779	13,699	10,138–17,261
Other	17,613	7859	9730	9754	7315–12,192

^aPropensity score with inverse probability of treatment weighting was used to adjust for baseline demographic and clinical characteristics. The predicted costs were estimated by using the generalized linear model coefficients for the adverse event and control cohorts, adopting recycled predictions.

CI indicates confidence interval; CNS, central nervous system.